ORLANDO — Drugs commonly used in cancer immunotherapy carry the risk for ocular adverse events, according to a speaker.
In a presentation at Cornea Subspecialty Day at the American Academy of Ophthalmology meeting, Meghan Berkenstock, MD, of Wilmer Eye Institute, said antibody-drug conjugates (ADCs) were “revolutionary,” providing new treatment options for patients who previously failed second- or third-line agents.
“We as ophthalmologists need to know what the ocular side effects of these drugs are because you will see these patients, and as a class, they cause several adverse events,”